News & Events

The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Impel NeuroPharma Closes $67.5 Million Series D Financing

SEATTLE, December 6th, 2018 — Impel NeuroPharma (“Impel” or the “Company”), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs, today announced that it has completed a…

Impel NeuroPharma Appoints Ellen A. Lubman As Chief Business Officer

SEATTLE, Nov. 7, 2018 /PRNewswire/ — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (CNS) disorders with unmet medical needs, today announced the appointment of Ellen A. Lubman as Chief…

Impel NeuroPharma Announces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

SEATTLE, August 29, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-and-active controlled…

Impel NeuroPharma Announces First Patient Dosed in Phase 3 Trial Evaluating INP104 for the Treatment of Acute Migraine Headache

SEATTLE, August 22, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the Company’s Phase 3, open-label safety and…

Impel NeuroPharma Strenthens Leadership Team With Appointment Of Lynn C. Gold As Senior Vice President Of Regulatory Affairs

SEATTLE, July 16, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory…

Impel NeuroPharma to Present New Data on INP104 for Treatment of Acute Migraine at 2018 Annual American Headache Society Meeting

SEATTLE, June 26, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced new data from the Company’s investigational drug INP104 for acute migraine will be presented…

Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine

SEATTLE, June 22, 2018 — Impel NeuroPharma today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of INP104, a novel, dihydroergotamine (DHE) product dosed via Impel’s proprietary Precision…

Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson’s Disease OFF Episodes

SEATTLE, May 31, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of a Phase IIa study designed to explore the safety and pharmacodynamic…

Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache

SEATTLE, Feb. 7, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced positive results from a recently completed Phase 1 proof-of-concept trial of INP104 for acute migraine…